arrow
M

Miljen Martić

novartis institutes for biomedical research
H指数:13
被引数:1,569

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study

作者更正:MASLD中脂肪性肝炎和纤维化成像及血清诊断生物标志物的前瞻性验证:LITMUS成像研究

2026-11-190
OAAI
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study

MASLD中脂肪性肝炎和纤维化影像学及血清学诊断生物标志物的前瞻性验证:LITMUS影像学研究

2026-07-240
OA
Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction-Associated Steatohepatitis

临床试验:一项评估代谢功能障碍相关脂肪性肝炎单药疗法和联合治疗方案的第2期随机平台研究

2025-11-012
OA
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

基于与人类代谢功能障碍相关的脂肪变性肝病 (MASLD) 的接近程度,对小鼠饮食模型进行无偏排名

2024-06-1233
OA
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

非酒精性脂肪性肝病患者临床结局的非侵入性检测和组织学预测: 个体参与者数据荟萃分析

2023-08-0180
OAAI
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

Tropifexor加cenicriviroc组合与单药治疗非酒精性脂肪性肝炎: 2b期串联研究的结果

2023-05-1119
OAAI
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

托普非索用于治疗非酒精性脂肪性肝炎:一项适应性、随机、安慰剂对照的2a/2b期临床试验

2023-02-1668
OAAI
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

Licogliflozin治疗非酒精性脂肪性肝炎: 一项随机,双盲,安慰剂对照的2a期研究

2022-06-2031
OA
LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia

LLF580,一种FGF21类似物,可降低中度高甘油三酯血症肥胖成人的甘油三酯和肝脂肪

2021-08-2533
OA
Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results
2020-02-0133
PREAI